Osteopontin Dynamics in Cancer Progression and Immune Regulation

Osteopontin is a multifunctional glycoprotein that bridges cell signalling, extracellular matrix remodelling and immune modulation within the tumour context. Elevated osteopontin expression is found in a broad spectrum of carcinomas, where it correlates with higher tumour grade, enhanced metastatic potential and poorer patient prognosis. By engaging integrins and CD44 receptors, osteopontin promotes cancer cell survival, invasion and angiogenesis while orchestrating immune cell recruitment and phenotype. In the tumour microenvironment, osteopontin acts in both autocrine and paracrine modes to foster a pro-tumourigenic niche, polarising macrophages towards immune-suppressive states, inhibiting cytotoxic T-cell activation and diminishing the efficacy of immunotherapies. Its multifaceted roles render osteopontin a compelling biomarker and therapeutic target for precision oncology.

Research from Nature Portfolio

Recent studies have demonstrated that tumour cell-derived osteopontin operates both autocrine and paracrine functions to sustain tumour recurrence and immune suppression. In models of breast cancer recurrence, osteopontin was shown to drive tumour cell proliferation, recruit macrophages and synergise with interleukin-4 to adopt a pro-tumourigenic phenotype. Inhibition of osteopontin reduced metastatic burden, opened the microenvironment to T-cell infiltration and enhanced the efficacy of checkpoint blockade therapy. Clinically, recurrent metastatic lesions exhibit higher osteopontin levels, increased macrophage infiltration and resistance to standard treatments, underscoring its value as an actionable target in recurrent malignancies.

Osteopontin Dynamics in Cancer Progression and Immune Regulation publication trend

The graph below shows the total number of articles in osteopontin dynamics in cancer progression and immune regulation across all publications each year (not limited to Nature Index journals).

Technical terms

Osteopontin (OPN): A secreted phosphoglycoprotein that functions as a cytokine and extracellular matrix component, involved in cell adhesion, migration and signalling.

Tumour microenvironment: The complex milieu surrounding cancer cells, including immune cells, stromal elements and extracellular matrix, which collectively influence tumour growth and therapy response.

Macrophage polarization: The process by which macrophages adopt distinct activation states ranging from pro-inflammatory (M1) to pro-tumourigenic (M2) phenotypes in response to environmental cues.

Autocrine and paracrine signalling: Modes of cellular communication in which secreted factors act upon the same cell (autocrine) or neighbouring cells (paracrine) to elicit biological effects.

Proteostasis: The maintenance of cellular protein balance through coordinated synthesis, folding, trafficking and degradation pathways.

Ubiquitin–proteasome system (UPS): A protein clearance mechanism in which target proteins are tagged by ubiquitin for degradation by the proteasome, regulating cellular homeostasis and signalling.

References

1. Osteopontin is a therapeutic target that drives breast cancer recurrence. Nature Communications (2024).
2. Osteopontin depletion in macrophages perturbs proteostasis via regulating UCHL1-UPS axis and mitochondria-mediated apoptosis. Frontiers in Immunology (2023).
3. The role of osteopontin in the progression of solid organ tumour. Cell Death & Disease (2018).
4. Role of osteopontin in the pathophysiology of cancer. Matrix Biology (2014).
5. Osteopontin is a marker for cancer aggressiveness and patient survival. British Journal of Cancer (2010).
6. Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation. Cancers (2020).